<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002142</url>
  </required_header>
  <id_info>
    <org_study_id>216B</org_study_id>
    <secondary_id>GS-93-107</secondary_id>
    <nct_id>NCT00002142</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS</brief_title>
  <official_title>An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with&#xD;
      relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in&#xD;
      this patient population. To evaluate the impact of cidofovir therapy on visual acuity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive intravenous HPMPC either at one dose for both induction&#xD;
      and maintenance or at a higher dose for induction than for maintenance. Induction consists of&#xD;
      two consecutive weekly doses followed by maintenance every other week. All patients receive&#xD;
      concomitant probenecid and saline hydration. Treatment continues until retinitis progression,&#xD;
      as assessed by retinal photographs, or treatment-limiting toxicity occurs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral agents.&#xD;
&#xD;
          -  Oral trimethoprim/sulfamethoxazole.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Filgrastim (G-CSF).&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  HIV vaccines.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  CMV retinitis, with severity as specified in the Disease Status field.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known clinically significant allergy to probenecid.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive&#xD;
             heart failure, or arrhythmia.&#xD;
&#xD;
          -  Other active medical problems sufficient to hinder study compliance.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Vidarabine.&#xD;
&#xD;
          -  Intravenous pentamidine.&#xD;
&#xD;
          -  CMV hyperimmune immunoglobulin.&#xD;
&#xD;
          -  Other nephrotoxic or potentially nephrotoxic agents.&#xD;
&#xD;
          -  Other investigational agents with anti-CMV activity.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Intravenous or oral acyclovir (except following development of herpetic lesion).&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Diuretics.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 days prior to study entry:&#xD;
&#xD;
          -  Ganciclovir or foscarnet.&#xD;
&#xD;
        Excluded within one week prior to study entry:&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Vidarabine.&#xD;
&#xD;
          -  Intravenous pentamidine.&#xD;
&#xD;
          -  CMV hyperimmune immunoglobulin.&#xD;
&#xD;
          -  Other nephrotoxic agents.&#xD;
&#xD;
          -  Other investigational agents with anti-CMV activity.&#xD;
&#xD;
        Excluded at any time:&#xD;
&#xD;
        Prior systemic or intravitreal HPMPC.&#xD;
&#xD;
        Drug or alcohol abuse that is considered sufficient to hinder study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Besselaar Associates</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>085406681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stagg RJ, et al. The Vistide (cidofovir injection) treatment IND for relapsing CMV retinitis (CMV-R). 4th Conf Retro and Opportun Infect. 1997 Jan 22-26;:120 (abstract no 306)</citation>
  </reference>
  <verification_date>October 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Retinitis</keyword>
  <keyword>Probenecid</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>cidofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

